KR20030014958A - 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 - Google Patents
올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 Download PDFInfo
- Publication number
- KR20030014958A KR20030014958A KR1020010048880A KR20010048880A KR20030014958A KR 20030014958 A KR20030014958 A KR 20030014958A KR 1020010048880 A KR1020010048880 A KR 1020010048880A KR 20010048880 A KR20010048880 A KR 20010048880A KR 20030014958 A KR20030014958 A KR 20030014958A
- Authority
- KR
- South Korea
- Prior art keywords
- oligonucleotide
- micelle
- micelles
- aliphatic polyester
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
- (ⅰ) 지방족 폴리에스테르계 생분해성 고분자 및 활성화제를 유기용매하에 반응시켜서 고분자를 활성화시키고, 건조시키는 공정;(ⅱ) 전기 활성화된 고분자와 5'-말단에 아민기를 포함하는 올리고뉴클레오티드를 2:1 내지 1:2의 몰비로 혼합하고, 유기용매에서 반응시켜서 접합체를 작제하는 공정; 및,(ⅲ) 전기 접합체를 증류수에 분산시켜서 미셀을 형성하는 공정을 포함하는 올리고뉴클레오티드 혼성화 미셀의 제조방법.
- 제 1항에 있어서,지방족 폴리에스테르계 생분해성 고분자는 폴리락트산(PLA), 폴리글리콜산(PGA), 폴리(D,L-락트산-co-글리콜산, PLGA), 폴리카프로락톤, 폴리발레로락톤, 폴리하이드록시 부티레이트, 폴리하이드록시 발러레이트 또는 이들의 혼합물인 것을 특징으로 하는올리고뉴클레오티드 혼성화 미셀의 제조방법.
- 제 1항에 있어서,활성화제는 디클로로헥실카보디이미드(DCC), p-나이트로페닐클로로포르메이트(p-nitrophenylchloroformate), 카보닐디이미다졸(CDI),N,N′-디숙신이미딜 카보네이트(N,N′-disuccinimidyl carbonate),N-하이드록실숙신이미드(NHS) 또는 이들의 혼합물인 것을 특징으로하는올리고뉴클레오티드 혼성화 미셀의 제조방법.
- 제 1항에 있어서,유기용매는 디메틸설폭사이드(dimethylsulfoxie, DMSO)인 것을특징으로 하는올리고뉴클레오티드 혼성화 미셀의 제조방법.
- 제 1항의 방법으로 제조되어, 5'-말단 인산기에 아민기(-NH2)를 포함하는 올리고뉴클레오티드와 지방족 폴리에스테르계 생분해성 고분자를 포함하는 올리고뉴클레오티드 혼성화 미셀.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0048880A KR100411234B1 (ko) | 2001-08-14 | 2001-08-14 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0048880A KR100411234B1 (ko) | 2001-08-14 | 2001-08-14 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030014958A true KR20030014958A (ko) | 2003-02-20 |
KR100411234B1 KR100411234B1 (ko) | 2003-12-18 |
Family
ID=27719109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0048880A KR100411234B1 (ko) | 2001-08-14 | 2001-08-14 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100411234B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100449889B1 (ko) * | 2001-08-30 | 2004-09-22 | 동국제약 주식회사 | 음이온 고분자와 인지질의 결합체가 함유된 인지질 리포좀및 그의 제조방법과 응용 |
KR100466254B1 (ko) * | 2002-02-25 | 2005-01-14 | 한국과학기술원 | 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101184928B1 (ko) * | 2009-05-14 | 2012-09-20 | 한국과학기술연구원 | 작은 올리고뉴클레오티드의 중합 방법 및 상기 중합 방법에 의하여 제조된 고분자 올리고뉴클레오티드의 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265389B1 (en) * | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6270795B1 (en) * | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
NZ332666A (en) * | 1996-05-08 | 2000-05-26 | Nika Health Products Ltd | Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
WO1998058630A1 (en) * | 1997-06-23 | 1998-12-30 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
-
2001
- 2001-08-14 KR KR10-2001-0048880A patent/KR100411234B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100449889B1 (ko) * | 2001-08-30 | 2004-09-22 | 동국제약 주식회사 | 음이온 고분자와 인지질의 결합체가 함유된 인지질 리포좀및 그의 제조방법과 응용 |
KR100466254B1 (ko) * | 2002-02-25 | 2005-01-14 | 한국과학기술원 | 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR100411234B1 (ko) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9567430B2 (en) | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery | |
KR101564796B1 (ko) | 비하전성 친수성 블록 및 측사슬의 일부에 소수성 기가 도입된 카티온성 폴리아미노산 블록을 포함하여 이루어지는 공중합체, 그 사용 | |
US8324365B2 (en) | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof | |
Zhou et al. | Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors | |
CN1646174B (zh) | 可控降解的聚合生物分子或药物载体及其合成方法 | |
CA2717778C (fr) | Polymere derive de la polyethylenimine lineaire pour le transfert de gene | |
US9241898B2 (en) | Compositions and methods for controlled delivery of inhibitory ribonucleic acids | |
CN101952434B (zh) | 使用合成的聚合物递送对基因沉默有活性的核酸的工具 | |
US20100196277A1 (en) | Nanoparticle compositions for controlled delivery of nucleic acids | |
EP2399948B1 (en) | Cationic poly-amino acids and uses thereof | |
US11814464B2 (en) | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | |
US20230233693A1 (en) | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery | |
JP5804453B2 (ja) | 結晶性ポリオール微粒子及びその調製方法 | |
Kedracki et al. | DNA–polymer conjugates: from synthesis, through complex formation and self-assembly to applications | |
KR100411234B1 (ko) | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 | |
Xia et al. | Triplex Hybridization of siRNA with Bifacial Glycopolymer Nucleic Acid Enables Hepatocyte-Targeted Silencing | |
KR100466254B1 (ko) | 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법 | |
Zhang et al. | Calcium phosphate/DNA co‐precipitates encapsulated fast‐degrading polymer films for substrate‐mediated gene delivery | |
JP2011010549A (ja) | ポリエチレングリコールの結合した核酸のコンジュゲートとリン酸カルシウムの有機−無機ハイブリッド型ナノ粒子 | |
WO2023108076A9 (en) | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues | |
Kiatwuthinon | Synthetic Dna Nanomaterials For Drug Delivery And 3D Cell Culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121011 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20130904 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150909 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160912 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170926 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190909 Year of fee payment: 17 |